Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Cancer Res. 2011 Aug 8;71(19):6195–6207. doi: 10.1158/0008-5472.CAN-11-1630

Figure 3.

Figure 3

CpG Methylation Biomarkers of ER-positive versus ER-negative subtypes in primary tumors. In the left panel (Discovery set, JH) CpG loci were evaluated using 103 primary tumors. The Y-axis: β-methylation, X-axis: Breast cancer samples, and N: normal breast organoids. The ER-status of the tumors is denoted on top of each box. Right panel (TCGA validation set), shows validation on an independent dataset (n=50) from TCGA. Shown are representative novel (A) and previously known (B) CpG loci specifically hypermethylated in ER+ and ER− breast cancers.